Overview
Noah Goldstein is counsel to Porzio, Bromberg & Newman, P.C. and a member of the firm's Life Sciences Compliance and Regulatory Counseling Department.
Prior to joining the Firm, Noah worked in the compliance department at Beth Israel Deaconess Medical Center (BIDMC), a leading academic medical center in Boston, MA. There, Noah focused his work on corporate compliance and privacy matters. He managed a compliance hotline, educated employees on ethics and compliance issues, and collaborated on audits, investigations, guidance requests, and other matters related to corporate compliance, privacy, research, and industry interactions. Additionally, he contributed to compliance program development and integration activities for Beth Israel Lahey Health, a new healthcare system in Massachusetts that BIDMC is a part of. Noah also has previous law firm and consulting experience, and has done some legal and compliance work for the life sciences industry.
Noah received his J.D. from New England School of Law in Boston, MA and his B.A. from Lafayette College in Easton, PA. Noah also completed the Seton Hall Law U.S. Healthcare Compliance Certification Program.
Memberships
- American Health Law Association - Member (February 2024 - Present)
News
- Porzio, Bromberg & Newman Named Winner of Financial Times Innovative Lawyers in Healthcare & Life Sciences Award, 12/05/2023
- Porzio Promotes Noah C. Goldstein, Caitlin M. Nolan, Raquel R. Rivera and Sara R. Simon to Counsel , 7/01/2023
- Noah Goldstein Joins the Massachusetts office of the Life Sciences Team, 7/06/2020
Articles
- Clinical Trial Recruitment: Who Are You Paying And What Are You Saying? – Clinical Leader, 7/15/2024
- The More Things Change, the More They Stay the Same: Government Scrutiny of Financial Arrangements Continues, 1/18/2024
- OIG's New General Compliance Program Guidance (GCPG): Overview and Takeaways for Life Sciences Companies, 11/17/2023
Speaking Engagements
-
"Clinical and R&D Compliance –Emerging Trends and New Risk Areas," Informa Pharmaceutical Compliance Congress, 4/16/2024
-
"Assessing Compliance Priorities: Considerations for Conducting an Effective and Collaborative Compliance Risk Assessment," 24th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, 10/25/2023